Subtopic Deep Dive
Hyperthermic Intraperitoneal Chemotherapy
Research Guide
What is Hyperthermic Intraperitoneal Chemotherapy?
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) delivers heated chemotherapy directly into the peritoneal cavity during or after cytoreductive surgery to treat peritoneal carcinomatosis from appendiceal and other malignancies.
HIPEC combines hyperthermia at 41-43°C with drugs like cisplatin, paclitaxel, or oxaliplatin to enhance tumor penetration and cytotoxicity. Randomized trials show HIPEC plus cytoreduction improves survival over systemic therapy alone in select colorectal and ovarian peritoneal cancers (Verwaal et al., 2003; Armstrong et al., 2006). Over 10 major trials with >2000 citations establish protocols and outcomes.
Why It Matters
HIPEC extends median survival from 6-8 months to over 20 months in peritoneal carcinomatosis from colorectal cancer (Verwaal et al., 2003; Gléhen et al., 2004). In ovarian cancer stage III, HIPEC during interval cytoreduction yields longer recurrence-free survival without added toxicity (van Driel et al., 2018). For pseudomyxoma peritonei from appendiceal origin, cytoreduction plus HIPEC achieves long-term disease-free survival in heterogeneous cases (Chua et al., 2012). Multi-institutional data confirm efficacy across 523 colorectal cases (Élias et al., 2009).
Key Research Challenges
Patient Selection Criteria
Identifying candidates with low tumor burden (completeness of cytoreduction score <2) remains critical, as poor selection negates survival benefits (Verwaal et al., 2003). Peritoneal Cancer Index (PCI) thresholds vary by origin, complicating standardization (Sugarbaker, 1995; Gléhen et al., 2004).
Drug Penetration Limits
Hyperthermia enhances cytotoxicity but tissue penetration of agents like oxaliplatin is limited to 2-3 mm, restricting efficacy against deeper nodules (Élias et al., 2008). Trials show variable pharmacokinetics across ovarian vs. colorectal cases (Armstrong et al., 2006).
Morbidity and Toxicity
HIPEC causes grade 3-4 myelosuppression and anastomotic leaks in 10-20% of cases, comparable to systemic arms but with higher surgical risks (van Driel et al., 2018). Long-term follow-up reveals bowel obstruction in 25% (Verwaal et al., 2008).
Essential Papers
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel et al. · 2006 · New England Journal of Medicine · 2.6K citations
As compared with intravenous paclitaxel plus cisplatin, intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival in patients with optimally debulked stage III ovarian ...
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer
Victor J. Verwaal, Serge van Ruth, Eelco de Bree et al. · 2003 · Journal of Clinical Oncology · 2.0K citations
Purpose: To confirm the findings from uncontrolled studies that aggressive cytoreduction in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) is superior to standard treatment in p...
Peritonectomy Procedures
Paul H. Sugarbaker · 1995 · Annals of Surgery · 1.5K citations
Peritonectomy procedures and preparation of the abdomen for early postoperative intraperitoneal chemotherapy were described. The author has used the cytoreductive approach to achieve long-term, dis...
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Willemien J. van Driel, Simone N. Koole, Karolina Sikorska et al. · 2018 · New England Journal of Medicine · 1.4K citations
Among patients with stage III epithelial ovarian cancer, the addition of HIPEC to interval cytoreductive surgery resulted in longer recurrence-free survival and overall survival than surgery alone ...
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
David S. Alberts, P. Y. Liu, Edward V. Hannigan et al. · 1996 · New England Journal of Medicine · 1.2K citations
As compared with intravenous cisplatin, intraperitoneal cisplatin significantly improves survival and has significantly fewer toxic effects in patients with stage III ovarian cancer and residual tu...
Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study
Olivier Gléhen, Fabrice Kwiatkowski, Paul H. Sugarbaker et al. · 2004 · Journal of Clinical Oncology · 1.2K citations
Purpose The three principal studies dedicated to the natural history of peritoneal carcinomatosis (PC) from colorectal cancer consistently showed median survival ranging between 6 and 8 months. New...
Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Terence C. Chua, Brendan Moran, Paul H. Sugarbaker et al. · 2012 · Journal of Clinical Oncology · 1.0K citations
Purpose Pseudomyxoma peritonei (PMP) originating from an appendiceal mucinous neoplasm remains a biologically heterogeneous disease. The purpose of our study was to evaluate outcome and long-term s...
Reading Guide
Foundational Papers
Start with Sugarbaker (1995) for peritonectomy techniques enabling HIPEC; Verwaal et al. (2003) for first randomized colorectal trial; Armstrong et al. (2006) for ovarian intraperitoneal chemotherapy survival gains.
Recent Advances
van Driel et al. (2018) NEJM trial on HIPEC in ovarian cancer; Chua et al. (2012) multi-center PMP outcomes; Élias et al. (2009) French registry of 523 colorectal cases.
Core Methods
Cytoreductive surgery with peritonectomies (Sugarbaker, 1995); hyperthermic perfusion circuits with mitomycin-C/oxaliplatin (Verwaal et al., 2003); PCI scoring for completeness (Gléhen et al., 2004).
How PapersFlow Helps You Research Hyperthermic Intraperitoneal Chemotherapy
Discover & Search
Research Agent uses searchPapers and citationGraph on Verwaal et al. (2003) to map 2000+ citing trials comparing HIPEC vs. systemic therapy in colorectal carcinomatosis. exaSearch finds protocol variations; findSimilarPapers clusters ovarian HIPEC studies like Armstrong et al. (2006) and van Driel et al. (2018).
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival curves from Verwaal et al. (2008) 8-year follow-up, then runPythonAnalysis with pandas for Kaplan-Meier meta-analysis across Gléhen et al. (2004) and Élias et al. (2009). verifyResponse (CoVe) and GRADE grading verify HIPEC's moderate evidence level for ovarian cancer (van Driel et al., 2018).
Synthesize & Write
Synthesis Agent detects gaps in appendiceal PMP protocols post-Chua et al. (2012), flags contradictions between colorectal trials (Verwaal vs. Élias). Writing Agent uses latexEditText, latexSyncCitations for trial comparison tables, and latexCompile for submission-ready reviews with exportMermaid for PCI score flowcharts.
Use Cases
"Extract survival data from HIPEC colorectal trials and compute pooled hazard ratios"
Research Agent → searchPapers('HIPEC colorectal Verwaal') → Analysis Agent → readPaperContent(Verwaal 2003,2008) + runPythonAnalysis(pandas meta-analysis of HRs) → researcher gets CSV of pooled survival stats with p-values.
"Draft LaTeX review of HIPEC in ovarian cancer trials with citations"
Research Agent → citationGraph(Armstrong 2006) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations(10 papers) + latexCompile → researcher gets PDF manuscript with formatted tables.
"Find code for HIPEC pharmacokinetic modeling from papers"
Research Agent → paperExtractUrls(Élias 2008 oxaliplatin) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for drug penetration simulations.
Automated Workflows
Deep Research workflow scans 50+ HIPEC papers via OpenAlex, structures survival meta-analysis report chaining searchPapers → citationGraph → runPythonAnalysis. DeepScan's 7-step verification analyzes Verwaal (2003) with CoVe checkpoints and GRADE scoring for trial quality. Theorizer generates hypotheses on hyperthermia synergies from Armstrong (2006) and Sugarbaker (1995) abstracts.
Frequently Asked Questions
What is HIPEC?
HIPEC is hyperthermic intraperitoneal chemotherapy, delivering heated drugs (41-43°C) into the peritoneum post-cytoreduction for peritoneal malignancies (Sugarbaker, 1995).
What are key methods in HIPEC?
Closed-abdomen perfusion with cisplatin/paclitaxel for ovarian or oxaliplatin for colorectal, lasting 60-90 min at hyperthermic temperatures (Verwaal et al., 2003; Élias et al., 2008).
What are seminal HIPEC papers?
Verwaal et al. (2003, 2001 citations) proved HIPEC superiority in colorectal carcinomatosis; Armstrong et al. (2006, 2600 citations) showed intraperitoneal benefit in ovarian cancer.
What open problems exist in HIPEC?
Optimal patient selection via PCI, deeper drug penetration beyond 3 mm, and phase III confirmation in appendiceal PMP remain unresolved (Chua et al., 2012; van Driel et al., 2018).
Research Intraperitoneal and Appendiceal Malignancies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hyperthermic Intraperitoneal Chemotherapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers